Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/305% above fair value
$68.29−0.21 (-0.31%)
Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –
Exelixis price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Exelixis's price to book ratio was 9.5× on Nov 11, 2026, against 5.5× a year earlier. Over the last 5 years it ranged from 2.1× to 9.5×, with a median of 3.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 9.5× | +4.1 |
| 2025 | Dec 31, 2025 | 5.4× | +1.3 |
| 2024 | Dec 31, 2024 | 4.2× | +1.0 |
| 2023 | Dec 29, 2023 | 3.2× | +1.1 |
| 2022 | Dec 30, 2022 | 2.1× | −0.7 |
| 2021 | Dec 31, 2021 | 2.7× | −0.6 |
| 2020 | Dec 31, 2020 | 3.4× | +0.0 |
| 2019 | Dec 31, 2019 | 3.3× | −18.3 |
| 2018 | Apr 30, 2018 | 21.6× | −51.1 |
| 2017 | Apr 28, 2017 | 72.7× | – |
See a number that looks wrong?